REG-Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
Royalty Pharma entered into a USD 100 million agreement to purchase royalty rights for Zealand Pharma's rusfertide (PTG-300), a potential first-in-class treatment for polycythemia vera. The transaction grants Royalty Pharma a 1% royalty on global net sales, with USD 50 million paid upfront and the remaining USD 50 million due one year after closing.
Key figures
- Drug Name
- rusfertide (PTG-300)
- Deal Value Usd
- 100000000
- Royalty rate
- 1%
- Upfront payment usd
- 50000000
- Deferred payment usd
- 50000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.